**Personal Commercial (63)**

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Relationship Category</th>
<th>Compensation Level</th>
<th>Topic Area(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott Laboratories</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td></td>
</tr>
<tr>
<td>Agios Pharmaceuticals</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td></td>
</tr>
<tr>
<td>AHA</td>
<td>Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director</td>
<td>Significant (&gt;= $5,000)</td>
<td></td>
</tr>
<tr>
<td>Alexion Pharma</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td></td>
</tr>
<tr>
<td>Alnylam</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td></td>
</tr>
<tr>
<td>Amgen Inc.</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td>Prevention</td>
</tr>
<tr>
<td>Angioneics</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td></td>
</tr>
<tr>
<td>Anthos Therapeutics</td>
<td>Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director</td>
<td>Significant (&gt;= $5,000)</td>
<td></td>
</tr>
<tr>
<td>ARCA</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td>Other</td>
</tr>
<tr>
<td>ARCA biopharma, Inc.</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td>Pulmonary Hypertension and Venous Thromboembolic</td>
</tr>
<tr>
<td>Array</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td></td>
</tr>
<tr>
<td>AstraZeneca Pharmaceuticals</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td>Prevention</td>
</tr>
<tr>
<td>Atentiv</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td></td>
</tr>
<tr>
<td>Audentes</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td></td>
</tr>
<tr>
<td>Bayer</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td>Prevention</td>
</tr>
<tr>
<td>Better Therapeutics</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td>Prevention</td>
</tr>
<tr>
<td>Brigham and Women's Hospital</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td></td>
</tr>
<tr>
<td>Bristol-Myers Squibb Company</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td></td>
</tr>
<tr>
<td>Cambrian Biopharma</td>
<td>Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director</td>
<td>Significant (&gt;= $5,000)</td>
<td></td>
</tr>
<tr>
<td>Cardiol Therapeutics</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td></td>
</tr>
<tr>
<td>CellResearch</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td></td>
</tr>
<tr>
<td>Clearfy</td>
<td>Other - Grant support to CPC</td>
<td>Significant (&gt;= $5,000)</td>
<td>Prevention</td>
</tr>
<tr>
<td>Cook Regentec</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td></td>
</tr>
<tr>
<td>CSL Behring</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td></td>
</tr>
<tr>
<td>Eidos Therapeutics</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td></td>
</tr>
<tr>
<td>EP Trading Company</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td></td>
</tr>
<tr>
<td>EPG Communications</td>
<td>Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director</td>
<td>Modest (&lt; $5,000)</td>
<td></td>
</tr>
<tr>
<td>Epizon Pharma</td>
<td>Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director</td>
<td>Significant (&gt;= $5,000)</td>
<td></td>
</tr>
<tr>
<td>Esperion</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td></td>
</tr>
<tr>
<td>EverlyWell</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td></td>
</tr>
<tr>
<td>Faraday Pharmaceuticals</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td></td>
</tr>
<tr>
<td>Company Name</td>
<td>Relationship Category</td>
<td>Compensation Level</td>
<td>Topic Area(s)</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>-----------------------</td>
<td>--------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>Fortress Biotech</td>
<td>Research/Research Grants</td>
<td>Significant (≥ $5,000)</td>
<td>Prevention</td>
</tr>
<tr>
<td>Heartflow</td>
<td>Research/Research Grants</td>
<td>Significant (≥ $5,000)</td>
<td></td>
</tr>
<tr>
<td>Insmid</td>
<td>Research/Research Grants</td>
<td>Significant (≥ $5,000)</td>
<td></td>
</tr>
<tr>
<td>Janssen Pharmaceuticals, Inc</td>
<td>Research/Research Grants</td>
<td>Significant (≥ $5,000)</td>
<td>Prevention</td>
</tr>
<tr>
<td>Kowa Research</td>
<td>Research/Research Grants</td>
<td>Significant (≥ $5,000)</td>
<td></td>
</tr>
<tr>
<td>Lexicon</td>
<td>Research/Research Grants</td>
<td>Significant (≥ $5,000)</td>
<td></td>
</tr>
<tr>
<td>Medtronic</td>
<td>Stock</td>
<td>Modest (&lt; $5,000)</td>
<td>Other</td>
</tr>
<tr>
<td>Merck &amp; Co., Inc.</td>
<td>Research/Research Grants</td>
<td>Significant (≥ $5,000)</td>
<td>Heart Failure and Cardiomyopathies</td>
</tr>
<tr>
<td>Moderna</td>
<td>Research/Research Grants</td>
<td>Significant (≥ $5,000)</td>
<td></td>
</tr>
<tr>
<td>NIH</td>
<td>Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director</td>
<td>Significant (≥ $5,000)</td>
<td></td>
</tr>
<tr>
<td>Novartis Corporation</td>
<td>Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director</td>
<td>Significant (≥ $5,000)</td>
<td></td>
</tr>
<tr>
<td>NovoNordisk</td>
<td>Research/Research Grants</td>
<td>Significant (≥ $5,000)</td>
<td>Vascular Medicine</td>
</tr>
<tr>
<td>Pfizer Inc</td>
<td>Stock</td>
<td>Modest (&lt; $5,000)</td>
<td>Other</td>
</tr>
<tr>
<td>Pfizer Inc</td>
<td>Research/Research Grants</td>
<td>Significant (≥ $5,000)</td>
<td></td>
</tr>
<tr>
<td>PhaseBio</td>
<td>Research/Research Grants</td>
<td>Significant (≥ $5,000)</td>
<td></td>
</tr>
<tr>
<td>PPD Development</td>
<td>Research/Research Grants</td>
<td>Significant (≥ $5,000)</td>
<td></td>
</tr>
<tr>
<td>Prothena Biosciences</td>
<td>Research/Research Grants</td>
<td>Significant (≥ $5,000)</td>
<td></td>
</tr>
<tr>
<td>Regeneron</td>
<td>Research/Research Grants</td>
<td>Significant (≥ $5,000)</td>
<td></td>
</tr>
<tr>
<td>Regio Biosciences</td>
<td>Research/Research Grants</td>
<td>Significant (≥ $5,000)</td>
<td></td>
</tr>
<tr>
<td>Sanofi-Aventis</td>
<td>Research/Research Grants</td>
<td>Significant (≥ $5,000)</td>
<td></td>
</tr>
<tr>
<td>Silence Therapeutics</td>
<td>Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director</td>
<td>Significant (≥ $5,000)</td>
<td></td>
</tr>
<tr>
<td>St. Luke's Hospital of Kansas City</td>
<td>Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director</td>
<td>Significant (≥ $5,000)</td>
<td></td>
</tr>
<tr>
<td>Stealth BioTherapeutics</td>
<td>Research/Research Grants</td>
<td>Significant (≥ $5,000)</td>
<td></td>
</tr>
<tr>
<td>Thrombosis Research Institute</td>
<td>Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director</td>
<td>Significant (≥ $5,000)</td>
<td></td>
</tr>
<tr>
<td>University of Colorado</td>
<td>Research/Research Grants</td>
<td>Significant (≥ $5,000)</td>
<td></td>
</tr>
<tr>
<td>University of Pittsburgh</td>
<td>Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director</td>
<td>Significant (≥ $5,000)</td>
<td></td>
</tr>
<tr>
<td>VarmX</td>
<td>Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director</td>
<td>Significant (≥ $5,000)</td>
<td></td>
</tr>
<tr>
<td>Vertex Pharmaceuticals</td>
<td>Stock</td>
<td>Significant (≥ $5,000)</td>
<td>Other</td>
</tr>
<tr>
<td>Worldwide Clinical Trials</td>
<td>Research/Research Grants</td>
<td>Significant (≥ $5,000)</td>
<td></td>
</tr>
<tr>
<td>Wraser</td>
<td>Research/Research Grants</td>
<td>Significant (≥ $5,000)</td>
<td>Vascular Medicine</td>
</tr>
<tr>
<td>Yale Cardiovascular Research Group</td>
<td>Research/Research Grants</td>
<td>Significant (≥ $5,000)</td>
<td></td>
</tr>
</tbody>
</table>

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record
Expert Witness Testimony (1)

<table>
<thead>
<tr>
<th>Year</th>
<th>Case Title</th>
<th>Represented</th>
<th>Description</th>
<th>Compensation</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>aortic dissection</td>
<td>Defendant</td>
<td>Missed aortic dissection</td>
<td>Significant (&gt;= $5,000)</td>
</tr>
</tbody>
</table>

Agreement

**Certified Education Attestation** | Signed on 2/10/2023
URL for full agreement: [http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement](http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement)

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 2/10/2023
URL for full agreement: [http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement](http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement)

**Embargo** | Signed on 2/10/2023
URL for full agreement: [http://disclosures.acc.org/Public/Definition/EmbargoAgreement](http://disclosures.acc.org/Public/Definition/EmbargoAgreement)

**On-Going Obligation Agreement** | Signed on 10/12/2023

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College’s integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.